GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cognetivity Neurosciences Ltd (OTCPK:CGNSF) » Definitions » Cash Conversion Cycle

Cognetivity Neurosciences (Cognetivity Neurosciences) Cash Conversion Cycle : 840.80 (As of Oct. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Cognetivity Neurosciences Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Cognetivity Neurosciences's Days Sales Outstanding for the three months ended in Oct. 2023 was 840.8.
Cognetivity Neurosciences's Days Inventory for the three months ended in Oct. 2023 was .
Cognetivity Neurosciences's Days Payable for the three months ended in Oct. 2023 was .
Therefore, Cognetivity Neurosciences's Cash Conversion Cycle (CCC) for the three months ended in Oct. 2023 was 840.80.


Cognetivity Neurosciences Cash Conversion Cycle Historical Data

The historical data trend for Cognetivity Neurosciences's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cognetivity Neurosciences Cash Conversion Cycle Chart

Cognetivity Neurosciences Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23
Cash Conversion Cycle
Get a 7-Day Free Trial - - - - 1,454.63

Cognetivity Neurosciences Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 281.80 3,208.96 939.88 840.80

Competitive Comparison of Cognetivity Neurosciences's Cash Conversion Cycle

For the Health Information Services subindustry, Cognetivity Neurosciences's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cognetivity Neurosciences's Cash Conversion Cycle Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cognetivity Neurosciences's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Cognetivity Neurosciences's Cash Conversion Cycle falls into.



Cognetivity Neurosciences Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Cognetivity Neurosciences's Cash Conversion Cycle for the fiscal year that ended in Jan. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=1454.63+-
=1,454.63

Cognetivity Neurosciences's Cash Conversion Cycle for the quarter that ended in Oct. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=840.8+-
=840.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cognetivity Neurosciences  (OTCPK:CGNSF) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Cognetivity Neurosciences Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Cognetivity Neurosciences's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Cognetivity Neurosciences (Cognetivity Neurosciences) Business Description

Traded in Other Exchanges
Address
800 West Pender Street, Suite 1430, Vancouver, BC, CAN, V6C 2V6
Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment for development of the ICA platform. Its geographical areas include Canada, United Kingdom and Dubai.

Cognetivity Neurosciences (Cognetivity Neurosciences) Headlines

From GuruFocus

The Most Innovative Healthcare AI Developments of 2019

By ACCESSWIRE AccessWire 04-12-2019